Synaptic disruption precedes neuronal death and correlates with clinical features of Alzheimer’s disease (AD). The identification of fluid biomarkers of synaptic damage is emerging as a goal for early and accurate diagnosis of the disease.
Objective:
To perform a systematic review and meta-analysis to determine whether fluid biomarkers of synaptic damage are impaired in AD.
Methods:
PubMed, Scopus, EMBASE, and Web of Science were searched for articles reporting synaptic proteins as fluid biomarkers in AD and cognitively unimpaired (CU) individuals. Pooled effect sizes were determined using the Hedge G method with random effects. Questions adapted from the Quality Assessment of Diagnostic Accuracy Studies were applied for quality assessment. A protocol for this study has been previously registered in PROSPERO (registration number: CRD42021277487).
Results:
The search strategy identified 204 articles that were assessed for eligibility. A total of 23 studies were included in the systematic review and 15 were included in the meta-analysis. For Neurogranin, 827 AD and 1,237 CU subjects were included in the meta-analysis, showing a significant increase in cerebrospinal fluid of patients with AD compared to CU individuals, with an effect size of 1.01 (p < 0.001). A significant increase in SNAP-25 and GAP-43 levels in CSF of patients with AD was observed.
Conclusion:
Neurogranin, SNAP-25, and GAP-43 are possible biomarkers of synaptic damage in AD, and other potential synaptic biomarkers are emerging. This meta-analysis also revealed that there are still relatively few studies investigating these biomarkers in patients with AD or other dementias and showed wide heterogeneity in literature.
HardyJ, AllsopD (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci12, 383–388.
3.
BraakH, BraakE (1991) Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol1, 213–216.
4.
TerryRD, MasliahE, SalmonDP, ButtersN, DeTeresaR, HillR, HansenLA, KatzmanR (1991) Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol30, 572–80.
5.
ArendtT (2009) Synaptic degeneration in Alzheimer’s disease. Acta Neuropathol118, 167–79.
Erten-LyonsD, WoltjerRL, DodgeH, NixonR, VorobikR, CalvertJF, LeahyM, MontineT, KayeJ (2009) Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology72, 354–360.
8.
SinghA, AllenD, FracassiA, TumurbaatarB, NatarajanC, ScadutoP, WoltjerR, KayedR, LimonA, KrishnanB, TaglialatelaG (2020) Functional integrity of synapses in the central nervous system of cognitively intact individuals with high Alzheimer’s disease neuropathology is associated with absence of synaptic tau oligomers. J Alzheimers Dis78, 1661–1678.
9.
MolinuevoJL, AytonS, BatrlaR, BednarMM, BittnerT, CummingsJ, FaganAM, HampelH, MielkeMM, MikulskisA, O’BryantS, ScheltensP, SevignyJ, ShawLM, SoaresHD, TongG, TrojanowskiJQ, ZetterbergH, BlennowK (2018) Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol136, 821–853.
10.
CamporesiE, NilssonJ, BrinkmalmA, BeckerB, AshtonNJ, BlennowK, ZetterbergH (2020) Fluid biomarkers for synaptic dysfunction and loss. Biomark Insights15, e1177271920950319.
11.
HuangKP, HuangFL, JägerT, LiJ, ReymannKG, BalschunD (2004) Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. J Neurosci47, 10660–10669.
12.
ThorsellA, BjerkeM, GobomJ, BrunhageE, VanmechelenE, AndreasenN, HanssonO, MinthonL, ZetterbergH, BlennowK (2010) Neurogranin in cerebrospinal fluid as a markerof synaptic degeneration in Alzheimer’s disease. Brain Res1362, 13–22.
13.
KvartsbergH, DuitsFH, IngelssonM, AndreasenN, ÖhrfeltA, AnderssonK, BrinkmalmG, LannfeltL, MinthonL, HanssonO, AndreassonU, TeunissenCE, ScheltensP, Van der Flier WM, ZetterbergH, PorteliusE, BlennowK (2015) Cerebrospinal fluidlevels of the synaptic protein neurogranin correlates with cognitivedecline in prodromal Alzheimer’s disease. Alzheimers Dement11, 1180–90.
14.
PorteliusE, ZetterbergH, SkillbäckT, TörnqvistU, AndreassonU, TrojanowskiJQ, WeinerMW, ShawLM, MattssonN, BlennowK, Alzheimer’s Disease Neuroimaging Initiative (2015) Cerebrospinal fluid neurogranin: Relation to cognition and neurodegeneration in Alzheimer’s disease. Brain138, 3373–3385.
15.
TarawnehR, D’AngeloG, CrimminsD, HerriesE, GriestT, FaganAM, ZipfelGJ, LadensonJH, MorrisJC, HoltzmanDM (2016) Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol73, 561–71.
16.
BrinkmalmA, BrinkmalmG, HonerWG, FrölichL, HausnerL, MinthonL, HanssonO, WallinA, ZetterbergH, BlennowK, ÖhrfeltA (2014) SNAP-25 is a promising novel cerebrospinal fluid biomarkerfor synapse degeneration in Alzheimer’s disease. MolNeurodegener9, 53.
17.
ÖhrfeltA, BrinkmalmA, DumurgierJ, BrinkmalmG, HanssonO, ZetterbergH, Bouaziz-AmarE, HugonJ, PaquetC, BlennowK (2016) The pre-synaptic vesicle protein synaptotagmin is a novel biomarkerfor Alzheimer’s disease. Alzheimers Res Ther8, 41.
18.
MoherD, LiberatiA, TetzlaffJ, AltmanDGPRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses The PRISMA statement.. PLoS Med6, e1000097.
19.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
20.
JackCR JrJr, AlbertMS, KnopmanDS, McKhannGM, SperlingRA, CarrilloMC, ThiesB, PhelpsCH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 257–262.
21.
DuboisB, FeldmanHH, JacovaC, DekoskyST, Barberger-GateauP, CummingsJ, DelacourteA, GalaskoD, GauthierS, JichaG, MeguroK, O’brienJ, PasquierF, RobertP, RossorM, SallowayS, SternY, VisserPJ, ScheltensP (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol6, 734–746.
Jelicic KadicA, VucicK, DosenovicS, SapunarD, PuljakL (2016) Extracting data from figures with software was faster, with higher interrater reliability than manual extraction. J Clin Epidemiol74, 119–123.
24.
WhitingPF, RutjesAW, WestwoodME, MallettS, DeeksJJ, ReitsmaJB, LeeflangMM, SterneJA, BossuytPM; QUADAS-2 Group (2011) QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med155, 529–536.
chatterjeeM, Del CampoM, MorremaTHJ, de WaalM, van der Flier WM, HoozemansJJM, TeunissenCE (2018) Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease. Alzheimers Res Ther10, 52.
28.
De VosA, StruyfsH, JacobsD, FransenE, KlewanskyT, De RoeckE, RobberechtC, Van BroeckhovenC, DuyckaertsC, EngelborghsS, VanmechelenE (2016) The cerebrospinal fluid neurogranin/BACE1 ratio is a potential correlate of cognitive decline in Alzheimer’s disease. J Alzheimers Dis53, 1523–1538.
29.
GalaskoD, XiaoM, XuD, SmirnovD, SalmonDP, DewitN, VanbrabantJ, JacobsD, VandersticheleH, VanmechelenE, Alzheimer’s Disease Neuroimaging Initiative (ADNI)WorleyP (2019) Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer’s disease. Alzheimers Dement5, 871–882.
30.
HampelH, ToschiN, BaldacciF, ZetterbergH, BlennowK, KilimannI, TeipelSJ, CavedoE, Melo Dos Santos A, EpelbaumS, LamariF, GenthonR, DuboisB, FlorisR, GaraciF, ListaSAlzheimer Precision Medicine Initiative (APMI)(2018) Alzheimer’s disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ142, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimers Dement14, 492–501.
31.
JanelidzeS, HertzeJ, ZetterbergH, Landqvist WaldöM, SantilloA, BlennowK, HanssonO (2015) Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol3, 12–20.
KesterMI, TeunissenCE, CrimminsDL, HerriesEM, LadensonJH, ScheltensP, van der Flier WM, MorrisJC, HoltzmanDM, FaganAM (2015) Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol72, 1275–1280.
34.
MerluzziAP, CarlssonCM, JohnsonSC, SchindlerSE, AsthanaS, BlennowK, ZetterbergH, BendlinBB (2018) Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. Neurology91, e436–e443
35.
SanfilippoC, ForlenzaO, ZetterbergH, BlennowK (2016) Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer’s disease and in mild cognitive impairment due to AD. J Neural Transm123, 1443–1447.
36.
Van HulleC, JonaitisEM, BetthauserTJ, BatrlaR, WildN, KollmorgenG, AndreassonU, OkonkwoO, BendlinBB, AsthanaS, CarlssonCM, JohnsonSC, ZetterbergH, BlennowK (2021) Anexamination of a novel multipanel of CSF biomarkers in theAlzheimer’s disease clinical and pathological continuum. Alzheimers Dement17, 431–445.
37.
WellingtonH, PatersonRW, PorteliusE, TörnqvistU, MagdalinouN, FoxNC, BlennowK, SchottJM, ZetterbergH (2016) Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology86, 829–835.
38.
AgliardiC, GueriniFR, ZanzotteraM, BianchiA, NemniR, ClericiM (2019) SNAP-25 in serum is carried by exosomes of neuronal origin and is a potential biomarker of Alzheimer’s disease. Mol Neurobiol56, 5792–5798.
39.
SutphenCL, McCueL, HerriesEM, XiongC, LadensonJH, HoltzmanDM, FaganAMADNI(2018) Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease. Alzheimers Dement14, 869–879.
40.
CamporesiE, LashleyT, GobomJ, Lantero-RodriguezJ, HanssonO, ZetterbergH, BlennowK, BeckerB (2021) Neuroligin-1 in brain and CSF of neurodegenerative disorders: Investigation for synaptic biomarkers. Acta Neuropathol Commun9, 19.
41.
DuitsFH, BrinkmalmG, TeunissenCE, BrinkmalmA, ScheltensP, Van der Flier WM, ZetterbergH, BlennowK (2018) Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease. Alzheimers Res Ther10, 5
42.
SandeliusÅ, PorteliusE, KällénÅ, ZetterbergH, RotU, OlssonB, ToledoJB, ShawLM, LeeVMY, IrwinDJ, GrossmanM, WeintraubD, Chen-PlotkinA, WolkDA, McCluskeyL, ElmanL, KostanjeveckiV, VandijckM, McBrideJ, TrojanowskiJQ, BlennowK (2019) Elevated CSF GAP-43 is Alzheimer’s disease specific andassociated with tau and amyloid pathology.. Alzheimers Dement15, 55–64.
43.
ZhangH, LyuD, JiaJ,
Alzheimer’s Disease Neuroimaging Initiative
(2022) The trajectory of cerebrospinal fluid growth-associated protein 43 in the Alzheimer’s disease continuum: A longitudinal study. J Alzheimers Dis85, 1441–1452.
44.
GoetzlEJ, KapogiannisD, SchwartzJB, LobachIV, GoetzlL, AbnerEL, JichaGA, KarydasAM, BoxerA, MillerBL (2016) Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease. FASEB J30, 4141–4148.
45.
WillemseEAJ, SiebenA, SomersC, VermeirenY, De RoeckN, TimmersM, Van BroeckhovenC, De VilB, CrasP, De Deyn PP, MartinJJ, TeunissenCE, EngelborghsS, BjerkeM (2021) Neurogranin as biomarker in CSF is non-specific to Alzheimer’s disease dementia. Neurobiol Aging108, 99–109.
46.
WangZ, YangJ, ZhuW, TangY, JiaJ (2021) The synaptic marker neurogranin as a disease state biomarker in Alzheimer’s disease: A systematic review and meta-analysis. Int J Neurosci10, 1–9.
47.
MavroudisIA, PetridisF, ChatzikonstantinouS, KazisD (2020) A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer’s disease and mild cognitive impairment. Aging Clin Exp Res32, 1639–1646.
48.
YoongSQ, LuJ, XingH, GyanwaliB, TanYQ, WuXV (2021) The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer’s disease continuum: A systematic review and meta-analysis with narrative synthesis. Ageing Res Rev72, 101491.
49.
DulewiczM, Kulczy’nska-PrzybikA, MroczkoB (2020) Neurograninand VILIP-1 as molecular indicators of neurodegeneration inAlzheimer’s disease: A systematic review and meta-analysis. IntJ Mol Sci21, 8335.
50.
Milà-AlomàM, BrinkmalmA, AshtonNJ, KvartsbergH, ShekariM, OpertoG, SalvadóG, FalconC, GispertJD, Vilor-TejedorN, Arenaza-UrquijoEM, Grau-RiveraO, Sala-VilaA, Sanchez-BenavidesG, González-de-EchávarriJM, MinguillonC, FauriaK, Niñerola-BaizánA, PerissinottiA, KollmorgenG, SuridjanI, ZetterbergH, MolinuevoJL, BlennowK, Suárez-CalvetMALFAStudy(2021) CSF synaptic biomarkers in the preclinical stage ofAlzheimer disease and their association with MRI and PET: Across-sectional study. Neurology97, e2065–e2078
51.
ChangCH, LinCH, LaneHY (2021) Machine learning and novel biomarkers for the diagnosis of Alzheimer’s disease. Int J Mol Sci22, 2761.
